ATF3 and neoplasm: A significant difference was observed in tumor size between the ATF3-siRNA + cisplatin group and the other groups by day 6 post-treatment (P<0.05), while inter-group comparisons among other groups revealed no significant difference (P>0.05; Fig. 10).